Fludarabine Phosphate

磷酸氟达拉滨

Report date: 2024/04/16 14:31:43
NME

Base Information

Drug NameFludarabine Phosphate
Drug Alias Name磷酸氟达拉宾fludarabinafludarabinum单磷酸氟达拉滨Fludarabine +[16] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionImmunosuppressantsDNA synthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsUveal melanomaSkin MelanomaSolid tumours +[22] 
Global Approved IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date1991/04/18
Country/TerritoryBelgiumUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSchering Deutschland GmbhUniversity Of Alabama At Birmingham
Inactive CompaniesUniversity of LiegeMasonic Cancer Center, University Of MinnesotaColorado Blood Cancer Institute +[12] 
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsUveal melanomaSkin MelanomaSolid tumours +[20] 

Other Information

ATC CodeL01BB05
Related LinksWikipediaDrugBankKEGG